Table 3.
Annualized eGFR slopes (ml/min per 1.73 m2 per year) according to duration of follow-up and by CKD stage or image classification
| 1–5 yr Follow-Up, n=58 | >5 yr Follow-Up, n=39 | Reference Populations | ||||
|---|---|---|---|---|---|---|
| Classification | Baseline to Last Follow-Up | Month 1 to Last Follow-Up | Baseline to Last Follow-Up | Month 1 to Last Follow-Up | TEMPO 3:4 Placeboa | REPRISE Placeboa |
| CKD stage | ||||||
| 1 | −1.22±4.13 [8] | 0.19±5.39 [8] | −1.69±1.52 [10] | −1.44±1.70 [10] | −2.55 (−3.20 to −1.90)b [162] | — |
| 2 | −1.36±2.50 [15] | −1.20±2.50 [15] | −2.27±1.68 [19] | −2.42±1.46 [19] | −3.9 (−4.42 to −3.37)b [216] | −4.65 (−6.24 to −3.05)b [38] |
| 3 | −2.80±2.11 [27] | −2.72±2.02 [27] | −2.09±1.39 [10] | −2.02±1.29 [10] | −5.36 (−6.19 to −4.53)b [84] | −4.16 (−4.50 to −3.81)b [500] |
| 4 | −3.25±0.91 [8] | −3.02±1.06 [8] | — | — | — | −4.60 (−5.09 to −4.12)b [125] |
| Total | −2.28±2.53 [58] | −1.96±2.89 [58] | −2.08±1.55 [39] | −1.97±1.57 [39] | −3.69 [462] | −3.61±0.24 [663] |
| Follow-up, yr | 2.65±1.42 | 2.56±1.10 | 7.60±1.74 | 7.51±1.73 | 3 | 1 |
| Age, yr | 46±9 | 46±9 | 41±9 | 41±9 | 39±7 | 47±8 |
| Men, n (%) | 24 (41) | 24 (41) | 12 (31) | 12 (31) | 248 (54) | 322 (49) |
| Irazabal image classc | ||||||
| 1A | 0.96 [1] | 2.47 [1] | — | — | — | — |
| 1B | −1.42±3.59 [7] | −1.53±2.99 [7] | −1.71±1.14 [9] | −1.62±1.14 [9] | −1.79 (−3.08 to −0.51)b [31] | — |
| 1C | −2.35±1.42 [13] | −1.80±2.00 [13] | −2.13±1.76 [16] | −2.05±1.75 [16] | −3.59 (−4.18 to −3.00)b [191] | — |
| 1D | −2.98±1.73 [12] | −2.59±1.70 [12] | −2.26±1.27 [7] | −2.16±1.30 [7] | −3.89 (−4.54 to −3.24)b [161] | — |
| 1E | −0.32±4.90 [5]d | 0.71±6.73[5]d | −2.74±1.95 [4] | −2.7±1.96 [4] | −4.93 (−5.87 to −3.99)b [82] | — |
| Total | −2.02±2.69 [38] | −1.56±3.16 [38] | −2.12±1.50 [36] | −2.04±1.50 [36] | — | — |
| Follow-up, yr | 2.9±1.2 | 2.8±1.2 | 7.7±1.8 | 7.6±1.8 | 3 | — |
| Age, yr | 43±9 | 43±9 | 42±9 | 42±9 | 39d | — |
| Men, n (%) | 15 (39) | 15 (39) | 12 (33) | 12 (33) | 248 (53) | — |
Values are expressed as mean±SD. Numbers in brackets represent the numbers of patients. TEMPO, Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes; REPRISE, Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD; —, not applicable.
eGFR data in the reference populations are reported at annualized means instead of slopes.
95% confidence interval.
Patients without baseline total kidney volume were included in the above CKD classification dataset but were not included in the image class dataset. Duration of follow-up, age, and sex are reported for each dataset.
One of the five patients in the 1–5 year 1E subgroup was a young patient with a relatively high baseline eGFR and a positive eGFR slope. This raised to average eGFR slope for that group (see Supplemental Figure 2).